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Quantitative clinical and autoimmune
assessments in stiff person syndrome:
evidence for a progressive disorder
Goran Rakocevic1, Harry Alexopoulos2 and Marinos C. Dalakas1,2*
Abstract
Background: Stiff Person Syndrome (SPS) is an under-diagnosed disorder that affects mobility and the quality of
life of affected patients. The aim of the study is to describe the natural history of SPS, the extent of accumulated
disability and the associated clinical and immunological features in patients followed for up to 8 years in a single
center.
Methods: Our collective cohort included 57 SPS patients. Additionally, 32 of these patients were examined every 6
months for a two-year period in a longitudinal study protocol, to assess disease progression using quantitative
measures of stiffness and heightened sensitivity.
Results: The most frequent initial symptom was leg stiffness, followed by paraspinal muscle rigidity and painful
spasms in 95% of the patients. Although none of the patients required assistance for ambulation during the first
2 years of disease onset, 46 patients (80%) lost the ability to walk independently during our follow-up, despite
symptomatic medications. In the longitudinal cohort, the number of stiff areas increased (p < 0.0001), consistent
with worsening functional status and quality of life. High-titer anti-GAD antibodies were present in serum and
CSF with elevated intrathecal GAD-specific IgG synthesis, but they did not correlate with clinical severity or progression.
Conclusions: This large study on SPS patients, combining an eight-year follow-up at a single center by the
same leading neurologist and his team, is the first to provide longitudinal data in a large patient subgroup
using objective clinical measures. One of the main findings is that SPS is a progressive disease leading to physical disability
over time.
Keywords: Stiff person syndrome, GAD, Autoimmune diseases, Inhibitory synapses
Background
Stiff Person Syndrome (SPS) is characterized by rigidity of
the truncal muscles with superimposed episodic and often
painful muscle spasms, heightened sensitivity to external
stimuli, particularly tactile and auditory, and high-titer
anti-GAD antibodies [1–6]. Co-contracture of agonist and
antagonist muscles and continuous involuntary firing of
motor units at rest are the cardinal pathophysiological
hallmarks of the disease [7, 8]. The patients also demon-
strate marked anticipatory anxiety and task-specific pho-
bias due to unexpected startle responses. SPS is often
associated with other autoimmune conditions, most com-
monly Type I diabetes, which is also an anti-GAD associ-
ated disease [9, 10].
Several clinical variants have been described including:
‘stiff-limb syndrome’, a limited form that spares the trunk
[11, 12]; a cerebellar variant (SPS-Cer) where cerebellar
symptoms are superimposed on the stiffness resulting in
prominent gait ataxia [4], a paraneoplastic variant mostly
associated with antibodies against amphiphysin or
gephyrin [13, 14]; SPS with myoclonus (‘jerking-man
syndrome’), associated with antibodies to glycine recep-
tor, now synonymous with Progressive Encephalomyeli-
tis with Rigidity and Myoclonus; and SPS with epilepsy
and dystonia [15–22].* Correspondence: marinos.dalakas@jefferson.edu1Department of Neurology, Thomas Jefferson University, Philadelphia, USA
2Neuroimmunology Unit, Department of Pathophysiology, Faculty of
Medicine, National and Kapodistrian University of Athens, Athens, Greece
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The symptoms are fluctuating and it is unclear
whether SPS patients accumulate disability over time.
We describe a series of patients, evaluated for up to 8
years in a single center with clinical, immunological,
imaging and neurophysiological measures and provide
prospective longitudinal data, in a subgroup of patients,
on disease progression using validated scales that quan-
tified stiffness and spasms.
Methods
Patient recruitment and follow-up assessments
Fifty seven SPS patients were recruited (1999–2006) at
the Neuromuscular Diseases Section of the National In-
stitutes of Health (NIH) after signing informed consent.
All patients were evaluated by the same senior clinician
(MCD) and his fellows (mostly GR who completed the
entire longitudinal study) and fulfilled the following
criteria [4, 6]: 1) insidious onset of rigidity in axial mus-
cles; 2) continuous co-contraction of agonist and antag-
onist muscles with inability to relax, as confirmed by
electrophysiology; 3) episodic spasms often triggered by
unexpected external stimuli or emotional upset; and 4)
no other neurological diseases that could account for
stiffness. Electromyography was assessed in all the pa-
tients either from patient records (n = 21) or performed
by us (n = 36). Brain MRI was performed in 44 patients
and was selectively repeated during the follow-up
period to exclude other processes or search for cerebel-
lar atrophy in those with concurrent cerebellar ataxia.
During the follow-up visits, all disease-related factors
were recorded, including frequency and condition of
falls, ability to work or carry out daily activities, concur-
rent medical and psychiatric illnesses, other neurological
or autoimmune diseases and response to medications.
Thirty-two patients were enrolled in a distinct longitu-
dinal study protocol, where Stiffness and Heightened Sensi-
tivity scores were systematically recorded using previously
validated scales [23], every 6 months for a two-year period,
to assess disease progression. During this period, the pa-
tients remained on their minimum tolerated doses of symp-
tomatic therapies including various muscle relaxants and
anti-anxiety drugs, but without immunotherapy at the
discretion of their treating neurologists. No precipitous
worsening of SPS symptoms occurred during this 2-year
follow-up in any of above patients; hence, no rescue
immunotherapies were administered. After this period, they
were offered participation in a rituximab trial or were
treated with IVIg.
Neuropsychiatric symptomatology
All patients were assessed for neuropsychiatric symp-
toms through structured interviews. The validated
Structured Interview for the Diagnostic and Statistical
Manual for Mental Disorders (DSM-IV) Axis I (SCID-I/P)
was additionally administered to 10 consecutive pa-
tients to explore the origin of anxiety and frequency of
phobic or other psychiatric disorders and assess their
personality characteristics and cognitive functioning, as
described [24].
Immunogenetics
Immunogenetic associations were investigated by HLA-I
and II allele-specific oligonucleotide typing in genomic
DNA extracted from peripheral blood of 34 patients and
compared to healthy controls from the NIH database
matched for age, ethnicity, and Type-I diabetes.
Immunological studies
The following autoantibodies were tested: anti-thyroid,
anti-parietal cell, anti-gliadin, intrinsic factor blocking anti-
body, anti-islet cell, ANA, anti-cardiolipin, anti-RNP, anti-
SSA/SSB, anti-SM, anti-striated, anti-smooth muscle, anti-
microsomal, anti-mitochondrial, anti-acetylcholine receptor,
anti-GM1, hepatitis B/C, HIV, HTLV-I and CMV. Im-
munoglobulin and complement levels were also tested.
Anti-GAD antibodies were initially tested in all pa-
tients and serially thereafter, in the 32 patients enrolled
in the longitudinal protocol, by radioimmunoassay (RIA)
using a commercial kit (Kronus, ID). Lumbar puncture
was performed in 48 patients but CSF could not be
obtained from 5 due to severe lumbar stiffness. CSF was
examined for GAD antibodies, total immunoglobulins,
oligoclonal bands, IgG index and intrathecal GAD-specific
IgG synthesis, as previously described [6, 25, 26].
Anti-GAD antibodies were also measured in serial CSF’s
(first and 2-year visits) in 10 patients by ELISA (Euroim-
mune, Lubeck). In 50 patients, sera were also tested for
anti-glycine receptor and anti-GABAA antibodies using
in-house cell-based immunofluorescent assays on live cells
(cDNA clones kindly provided by Prof. A. Vincent, Oxford
and Prof. J. Dalmau, Barcelona), as described [27].
Results
Among the 57 patients, 39 were women and 18 men (ratio
2:1); 46 were Caucasians and 11 African Americans. The
mean age of disease onset was 42 years (range, 22–60) and
the mean disease duration at enrollment 11 years (range,
3–32). The duration between symptom onset and time of
diagnosis was 5 years (range: 1–19).
Clinical presentation at onset
The most common initial symptom was insidious on-
set of proximal leg stiffness, reported by 19 patients
(33%). The second most common symptom was rigid-
ity in the lumbosacral paraspinal muscles (16 patients,
28%), followed by rigidity in the thoracic and abdom-
inal muscles (6 patients, 10%). When first examined,
axial muscle stiffness (truncal and proximal legs),
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lumbar hyperlordosis and impaired gait were detected
in 39 patients (68%); sixteen of them (28%) had also
various degrees of facial muscle stiffness (Table 1).
Muscle pain related to stiffness and spasms was re-
ported by all but two patients. Six patients (10%) had
asymmetric presentation in one limb (‘stiff-leg syn-
drome’), and two others also had severe abnormal
hand posturing (pseudo-dystonia). Isolated rigidity of
distal leg muscles resembling dystonia was the first
symptom in 3 patients. Prominent stiffness only in
cervical paraspinal muscles was the initial presentation
in one patient; in another, SPS was preceded by prom-
inent oscillopsia, opsoclonus and nystagmus.
Cerebellar symptoms including dysmetria, marked
gait ataxia or nystagmus, without axial muscle stiff-
ness, were the initial presentation in 5 patients (9%);
they too developed typical SPS after a mean period of
5 years (SPS-Cer) with prominent cerebellar symptom-
atology. All 5 SPS-Cer patients were positive for
anti-GAD antibodies.
Neuropsychiatric symptoms at onset
Exaggerated reaction to various external stimuli and
‘startle response’ was present in all patients except 2
without episodes of muscle spasms. Marked anxiety re-
lated to unprotected falls or in anticipation of physically
challenging situations was reported in 52 of 57 patients
(Table 1). Three patients had refractory depression that
coincided with the onset of SPS, while 21 patients expe-
rienced chronic anxiety combined with intermittently
depressed mood. Simple phobias, such as fear of walking
in open and crowded places, crossing a street or taking
escalators were reported by 7 patients. Four patients had
task-related phobias, such as fear of public speaking.
Formal neuropsychiatric testing in ten consecutive pa-
tients however, did not meet DSM-IV criteria for phobic
disorder [24]; the patients perceived their fears and anx-
iety as realistic arising from the possibility of falls caused
by SPS.
Several patients had been earlier misdiagnosed with
conversion or functional disorder because their falls
were attributed to avoidant behavior and heightened
mental anticipation. Other common misdiagnoses were
spinal disease, dystonia or Parkinsonism.
Three patients used alcohol as muscle relaxant prior
to diagnosis and finally became alcohol-dependent; two
others used cannabis and stimulants (crystal metham-
phetamine). Many patients reported muscle pain along
with painful spasms and some had been on narcotics.
Overall disease progression in an 8-year observational
period
Several patients exhibited diurnal fluctuations of stiffness
and spasms with worsening during periods of physical
or emotional stress, cold weather or concurrent infec-
tions. The stiffness often spread to the adjacent truncal
muscles sparing the distal and facial muscles until late in
the disease. Episodes of truncal stiffness were often
perceived as ‘freezing attacks’ and the sudden falls (due
to painful contractions) as seizures necessitating Emer-
gency Room visits for intravenous muscle relaxants. The
number of falls during the ambulatory phase averaged
up to four per month.
Although none of the patients required assistance for
ambulation during the first 1–2 years of disease onset,
46 (80%) lost the ability to walk independently during
the course of the disease, and despite receiving symp-
tomatic therapies 26 of them used a cane, 14 a walker
and 9 a wheel-chair (Table 1).
The frequency of painful spasms also progressed over
time but varied from twenty per day to a few per year and
their duration from minutes to hours (status spasticus), as
described [21]. In 11 patients (19%) spasms and stiffness
also affected the thoracic paraspinal and intercostal or dia-
phragmatic muscles resulting in respiratory distress. The
Table 1 Predominant distribution of stiffness and other neurological




Cervical paraspinal and shoulder girdle muscles 11 (19)
Thoracic paraspinal and abdominal wall muscles 14 (24)
Lumbosacral paraspinal muscles 16 (28)
Proximal leg muscles 17 (30)
Combined lumbosacral paraspinal and proximal leg muscles 33 (58)
Axial (diffuse paraspinal and proximal limb muscles) 39 (68)
Asymmetry with one limb predominant (stiff-limb) 6 (10)
Distal limb stiffness 4 (7)
Spasms 50 (88)
Other associated symptoms:
Ocular symptoms 13 (23)
Cerebellar symptoms and signs 7 (12)
Functional impairment resulting in the following:
Stiff or impaired gait 54 (94)
Hyperlordosis 48 (84)
Shortness of breath 11 (19)
Need for cane 26 (45)
Need for walker 14 (24)
Need for wheelchair 9 (15)
Inability to work 48 (84)
Startle response 55 (96)
Anxiety and task-specific phobias 52 (91)
Depressed mood 3 (5)
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majority (87%) reported episodic spasms in the areas
afflicted by the stiffness; the remaining, either had mild
disease or were responding well to symptomatic therapy.
Visual complaints were common. Eleven patients re-
ported double or blurred vision and those with cerebel-
lar ataxia prominent oculomotor dysfunction with
nystagmus and oscillopsia [26].
Symptom progression had finally exerted a significant
impact on the patients’ quality of life, independence and
ability to work. Although at disease onset only two pa-
tients quit their jobs due to falls and inability to drive,
after a mean period of 4 years only 11 of 57 patients
were able to work full or part-time; the majority were on
disability benefits.
During the study period, two patients died; one at age
42 from ruptured aneurysm, and another at age 55 due
to cardiac arrest of unclear etiology.
Disease progression with quantitative measures in 32
patients involved in a longitudinal 2-year study period
These patients’ progression was measured systematically
every 6 months using the Stiffness Index (maximum 6)
and Heightened Sensitivity scales (maximum 7). The
mean number of stiff areas at entry was 3.25 and the
mean heightened sensitivity score 3.40. Two years later,
without immunotherapy, the mean number of stiff areas
had increased to 4.15 (p < 0.0001) and the heightened
sensitivity to 3.65 (p < 0.5) (Fig. 1a, b). No changes in
numbers of affected areas were captured in 9 patients,
although their symptom severity increased as reflected
by the higher frequency of falls and impaired ability to
walk independently or perform their work duties. After
the two-year follow up period, five patients could no
longer function only with symptomatic therapy and re-
quested intermittent IVIg infusions with considerable
benefit. One GAD-positive patient developed metastatic
lung adenocarcinoma on study completion; her SPS im-
proved dramatically after chemotherapy.
Associated diseases at onset and follow-up
Seventeen of 57 patients (30%) developed autoimmune
thyroiditis (Table 2); eight became hypothyroid after sur-
gical or radiation treatment and six were on supplemen-
tal therapy. Sixteen patients (28%) had Type-1 diabetes
diagnosed within 1–3 years from onset of SPS. Eleven
patients (19%) had pernicious anemia, two vitiligo, one
rheumatoid arthritis and one IgGκ MGUS. Nine patients
(15%) had partial complex seizures which were focal or
infrequent and well controlled with anti-epileptics. Four
GAD-positive patients, without amphiphysin antibodies,
developed cancer (breast, prostate, skin, lung adenocar-
cinoma) several years after onset of SPS but all survived
cancer treatment. Two patients had benign tumors, one
choroid plexus papilloma and another acoustic neuroma.
Autoantibodies in serum and CSF: Serial studies
All patients had high-titer anti-GAD antibodies (mean
950 nmol/L, normal < 0.02, range: 0.43–11,000), but
their titers tested over time varied even in the same pa-
tient. There was no correlation between antibody titers
and clinical severity or fluctuation as assessed by Stiff-
ness Index and Heightened Sensitivity scores [6, 25].
Eight of 50 (16%) patients harbored anti-glycine receptor
antibodies [27]; none of them had anti-GABAA receptor
or paraneoplastic antibodies. Other organ-specific auto-
antibodies were however detected (Table 2).
Fig. 1 Analysis of stiffness and heightened sensitivity indices for the
32 serially analyzed patients over a 2-year course. a: Mean number
of stiff areas at 6 months intervals. There is a statistically significant
increase (p < 0.0001, Friedman test – One way ANOVA) in the
number of stiff areas (3.25 at 6months rising to 4.15 at 24months) during
the observation period. b: Mean number of heightened sensitivity scores
calculated at 6months intervals. The observed increase (3.40 vs 3.65) is not
statistically significant (p<0.1195, Friedman test – One way ANOVA)
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In the 32 longitudinally studied patients the anti-GAD
serum titers (expressed in Standard Units) ranged from
9000 to 62,000 (mean: 24,000; normal < 1.5) and their
CSF from 30 to 2000 (mean: 280; normal: 0). The mean
titer ratio of anti-GAD CSF/ serum was 0.01 (range,
0.004–0.024) and the mean ratio of CSF/ serum IgG was
0.002 (range, 0.001–0.005) indicating a 4-fold increase of
specific intrathecal GAD-IgG production. In 10 patients,
CSF was also repeatedly tested in a two-year period. The
mean titer after 2 years was lower (24,013 International
Units/ml vs 19,855 IU/ml) but this difference was not
statistically significant (two-tailed, paired t-test, p = 0.55)
(Fig. 2). Oligoclonal IgG bands were noted in 16 (28%)
patients with elevated IgG index in four.
In five SPS patients with cerebellar disease (SPS-Cer),
the mean ratio of anti-GAD CSF/ serum was 0.03 (range,
0.007–0.057) and the mean ratio of CSF/ serum IgG was
0.002 (range, 0.001–0.005), indicating a 10-fold increase
of intrathecal antibody production, 2.5-fold higher com-
pared to typical SPS [26], suggesting an enhanced B-cell
activation within the CNS, consistent with the more ex-
tensive neurological phenotype.
Several patients with prominent muscle rigidity and at-
tacks of muscle spasms showed persistently elevated creat-
ine kinase up to 1000U/L, but with normal muscle
strength. Muscle biopsies in 2 patients showed mild
lymphocytic infiltrates and up-regulation of MHC-I, indi-
cative of an indolent inflammatory autoimmune process
also affecting the muscle, as reported [6, 9, 21].
Electrophysiology and imaging
Electrophysiological work-up showed the typical for SPS
continuous firing of normal-appearing motor unit po-
tentials at rest with simultaneous co-activation of motor
units in agonist and antagonist muscles in 32 of 36
tested patients. Four patients did not complete the EMG
because they could not tolerate the procedure due to
stiffness and/or pain. Five mildly affected patients or
those responding favorably to symptomatic therapy with
GABA-enhancing drugs, exhibited normal electromyog-
raphy. MRI imaging (44/57 patients) was generally unin-
formative including the patients with SPS-Cer where no
atrophy was observed.
Immunogenetics
Alleles in the HLA-DR or DQ haplotype region, were
found in 33/57 tested patients, confirming previous ob-
servations [6, 28, 29]. The most frequent allele was the
DRB1* 0301, noted in 14/33 patients (42%) compared to
13% frequency seen in normal Caucasians; none of 4
tested African Americans had this allele. A significant
association was also noted with the HLA-DQB1* 0201
allele seen in 14/33 patients; seven of them also had
Table 2 Associated diseases and autoantibodies in SPS patients
Associated diseases n (%)
Autoimmune thyroiditis 17 (30)
Insulin dependant diabetes mellitus (IDDM) 16 (28)
Pernicious anemia (PA) 11 (19)
Epilepsy 9 (15)
Vitiligo 2 (3)
Rheumatoid arthritis 1 (1)
Autoimmune pancreatitis 1 (1)
Irritable bowl syndrome 1 (1)
Monoclonal gammopathy of unknown significance 1 (1)
Antibodies n (%)
Anti-nuclear antigen (ANA) 26 (45)
Anti-cardiolipin IgG and IgM (ACA) 10 (17)
(Anti-nuclear and cardiolipin antibodies together) 7 (12)
Thyroid peroxidase antibody 23 (40)
Anti-thyroglobulin antibody 20 (35)
(Thyroid peroxidase and thyroglobulin antibodies together) 16 (28)
Anti-thyroid microsomal antibody 1 (1)
Anti-parietal cell antibody 18 (31)
Anti-islet cell antibody 6 (10)
Anti-gliadin antibody 6 (10)
Intrinsic factor blocking antibody 3 (5)
Anti-JO-1 antibody 3 (5)
Anti-ENA (RNPSM) 2 (3)
Rheumatoid factor (RF) 1 (1)
Fig. 2 Comparison of CSF anti-GAD antibody titers within a 2-year
period. While there is a titer drop in the 2 year-period (mean 24,013
IU/ml vs 19,855 IU/ml) this difference is not statistically significant (p
= 0,55 two-tailed paired t-test)
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Type-1 diabetes and four autoimmune thyroiditis. Asso-
ciations with the DRB* 3*0101 locus was found in 11 pa-
tients and with the 3*0202 in 7. Five patients without
diabetes carried the DQB1*0602 protective allele; in con-
trast, none of the 9 tested patients with Type-1 Diabetes
carried this allele, suggesting that DQB1*0602 may be
associated with a reduced prevalence of diabetes among
SPS patients [28].
Discussion
We present detailed clinical and immunological 8-year
follow-up data from SPS patients examined in a single
center by the same leading clinician along with his team.
Most importantly, we present 2-year longitudinal data in
32 patients, without immunotherapy, which in spite of
variability in disease severity within the same patient,
demonstrate that SPS is a progressive disease that leads
to physical and social disability. The findings are import-
ant in the design of future therapies.
The delay in establishing diagnosis and initiating treat-
ment ranged from 1 to 19 years (mean, 5 years), confirm-
ing that SPS still remains a largely under-recognized
entity. Symptoms usually started subtly in patients below
the age of 50 and progressed slowly thereafter to per-
manent stiffness or impaired gait; in 15 patients with
disease onset > 50 however disability developed much
sooner. At first evaluation, the majority of patients (68%)
already had diffuse axial muscle stiffness with spasms,
hyperlordosis and impaired gait. 23% of patients who
started asymmetrically (‘stiff-limb syndrome’) or with
mild gait difficulties, ocular disturbances and cerebellar
symptomatology, eventually developed the typical SPS
phenotype. Anxiety alone or combined with task-specific
phobias and depressive mood were eventually universally
present resulting in severe social disability [24].
The main novelty of our study is the longitudinally ob-
tained quantitative clinical data from 32 patients which
unequivocally demonstrate that SPS is a progressive dis-
ease. This was complemented by increasing frequency of
falls, need for assistance in walking and daily activities
and progressively impaired ability to work in 84% of
these patients over the 2-year period. In spite of fluctua-
tions, the overall mean number of stiff areas increased
from 3.25 to 4.15 (Fig. 1a); this combined with more fre-
quent spasms, signifies that without immunotherapy
SPS is a steadily progressive disease that leads to disabil-
ity. The heightened sensitivity scores, based on a more
variable scale, remained fairly constant during the
two-year period (Fig. 1b).
The autoimmune nature of SPS was re-confirmed in our
series by the: a) presence of high-titer antibodies against
GAD in serum and CSF; b) glycine receptor antibodies
present in a patient subset; c) frequent association with
other autoimmune diseases and autoantibodies, including
thyroiditis and Type-1 diabetes; and d) a strong immu-
nogenetic association with DRB1*0301 and DQB1*
0201 haplotypes. Serum and CSF anti-GAD titers, in-
cluding serial 2-year assessment, did not correlate with
clinical severity confirming prior observations in
smaller cohorts [4, 6, 9, 21, 25].
The pathogenetic potential of anti-GAD antibodies re-
mains unsettled. The high rate of intrathecal synthesis of
GAD-specific IgG signifies B-cell in-situ stimulation in the
CSF compartment and possibly in-situ action of antibodies
within the CNS, but it is unclear what drives their CNS
persistence and why rituximab is ineffective [30]. The rea-
son for the apparent clinical heterogeneity among SPS pa-
tients is also uncertain. It was thought to be related to the
variable susceptibility of GABAergic neurons to
anti-GAD or other still unidentified autoantibodies
[31–33] but recent data from two independent studies
indicate that all anti-GAD antibodies from SPS or other
hyperexcitability syndromes recognize the same domin-
ant GAD epitope [34, 35].
A wide range of medications were used in our series for
symptomatic relief, most commonly GABA-enhancing
drugs such as sedative-anxiolytics, anti-spasticity and anti-
epileptic drugs. Among immunotherapies, high-dose IVIg,
as confirmed in a controlled study [23] was effective in a
number of patients. It is however puzzling why high-doses
of corticosteroids and common immunosuppressants in-
cluding the anti-B cell agent rituximab [30], which is suc-
cessfully used in a number of autoimmune neurological
diseases [36], have been rather disappointing in SPS ex-
cept of rare cases responding dramatically to rituximab.
Conclusions
The progressive and disabling nature of SPS as confirmed
in this series [37] indicates the need for prompt initiation of
more effective therapies. In particular, proven-to-work im-
munotherapies such as IVIg might be initiated early if there
are signs of clinical worsening, given the fact that SPS
symptoms are progressive, as our study demonstrated.
Abbreviations
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